Optimization of immunotherapy in elderly cancer patients

Critical Reviews in Oncogenesis

Volumn 18, Issue 6, 2013, Pages 573-583

  Tomihara, Kei ^a   Curiel, Tyler J ^b   Zhang, Bin ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Elderly; Immunosenescence; Immunotherapy; Optimization

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DENILEUKIN DIFTITOX; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TOLL LIKE RECEPTOR;

AGE DISTRIBUTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INTRACELLULAR SIGNALING; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; THERAPY EFFECT; TUMOR IMMUNITY;

AGED; AGING; ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84893137826     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013010591     Document Type: Article

References (103)

1. Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol. 1997;40:209-14.
2. Roche LM, Paul SM, Costa SJ. Acquired immune deficiency syndrome and the increase in non-Hodgkin lymphoma incidence in New Jersey from 1979 to 1996. Cancer. 2001;92:2948-56.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosur-veillance to tumor escape. Nat Immunol. 2002;3: 991-8.
4. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204-10.
5. Leach CT, Pollock BH, McClain KL, Parmley RT, Murphy SB, Jenson HB. Human herpesvirus 6 and cytomegalovirus infections in children with human immunodeficiency virus infection and cancer. Pediatr Infect Dis J. 2002;21:125-32.
6. Rodrigues LK, Klencke BJ, Vin-Christian K, Berger TG, Crawford RI, Miller JR 3rd, Ferreira CM, Nosrati M, Kashani-Sabet M. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol. 2002;138:765-70.
7. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11:537-50.
8. Vallejo AN. Immunological hurdles of ageing: indispensable research of the human model. Ageing Res Rev. 2011;10:315-8.
9. Miller RA. The aging immune system: primer and prospectus. Science. 1996;273:70-4.
10. Wick G, Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol. 1997;32:401-13.
11. Rosato E, Salsano F. Immunity, autoimmunity and autoimmune diseases in older people. J Biol Regul Homeost Agents. 2008;22:217-24.
12. Nikolich-Žugich J, Li G, Uhrlaub JL, Renkema KR, Smithey MJ. Age-related changes in CD8 T cell homeostasis and immunity to infection. Semin Immunol. 2012;24:356-64.
13. DePinho RA. The age of cancer. Nature. 2000;408:248-54.
14. Effros RB, Walford RL. The immune response of aged mice to influenza: diminished T cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol. 1983;81:298-305.
15. Jiang J, Anaraki F, Blank KJ, Murasko DM. Cutting edge: T cells from aged mice are resistant to depletion early during virus infection. J Immunol. 2003;171:3353-7.
16. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol. 2004;172:5194-9.
17. Linton PJ, Haynes L, Tsui L, Zhang X, Swain S. From naive to effector-alterations with aging. Immunol Rev. 1997;160:9-18.
18. Bloom ET, Umehara H, Bleackley RC, Okumura K, Mostowski H, Babbitt JT. Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice. Eur J Immunol. 1990;20:2309-16.
19. Bloom ET, Umehara H, Bleackley RC, Okumura K, Mostowski H, Babbitt JT. Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice. Eur J Immunol. 1990;20:2309-16.
20. Paganelli R, Quinti I, Fagiolo U, Cossarizza A, Ortolani C, Guerra E, Sansoni P, Pucillo LP, Scala E, Cozzi E, Bertollo L, Monti D, and Franceschi C. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol. 1992;90:351-4.
21. LeMaoult J, Szabo P, Weksler ME. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev. 1997;160:115-26.
22. Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today. 2000;21:515-21.
23. Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol. 2007;64:90-105.
24. Paula C, Motta A, Schmitz C, Nunes CP, Souza AP, Bonorino C. Alterations in dendritic cell function in aged mice: potential implications for immunotherapy design. Biogerontology. 2009;10:13-25.
25. Grolleau-Julius A, Abernathy L, Harning E, Yung RL. Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol Immunother. 2009;58:1935-9.
26. Facchini A, Mariani E, Mariani AR, Papa S, Vitale M, Manzoli FA. Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing. Clin Exp Immunol. 1987;68:340-7.
27. Rukavina D, Laskarin G, Rubesa G, Strbo N, Bedenicki I, Manestar D, Glavas M, Christmas SE, Podack ER. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood. 1998;92:2410-20.
28. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. J Leukoc Biol. 2004;76:291-9.
29. Mocchegiani E, Giacconi R, Cipriano C, Malavolta M. NK and NKT cells in aging and longevity: role of zinc and metallothioneins. J Clin Immunol. 2009;29:416-25.
30. Dejaco C, Duftner C, Schirmer M. Are regulatory T cells linked with aging? Exp Gerontol. 2006;41:339-45.
31. Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J Immunol. 2006;176:6586-93.
32. Shimizu J, Moriizumi E. CD4+CD25-T cells in aged mice are hyporesponsive and exhibit suppressive activity. J Immunol. 2003;170:1675-82.
33. Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, Wang J, Mountz JD, Zhang HG. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev. 2007;128:672-80.
34. Flood PM, Urban JL, Kripke ML, Schreiber H. Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med. 1981;154:275-90.
35. Urban JL, Schreiber H. Rescue of the tumor-specific immune response of aged mice in vitro. J Immunol. 1984;133:527-34.
36. Flood PM, Liu X, Alexander R, Schreiber H, Haque S. Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. J Immunother. 1998;21:307-16.
37. Schindowski K, Fröhlich L, Maurer K, Müller WE, Eckert A. Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev. 2002;123:375-90.
38. Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev. 2005;205:220-8.
39. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129-44.
40. Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol. 2002;169:5000-9.
41. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med. 2004;200:1613-22.
42. Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med. 1999;190:1013-24.
43. Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev. 2005;205:220-8.
44. Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL. CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly. Proc Natl Acad Sci U S A. 2003;100:15053-8.
45. Shimada Y, Hayashi M, Nagasaka Y, Ohno-Iwashita Y, Inomata M. Age-associated up-regulation of a negative co-stimulatory receptor PD-1 in mouse CD4+ T cells. Exp Gerontol. 2009;44:517-22.
46. Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N. PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Proc Natl Acad Sci U S A. 2009;106:15807-12.
47. Channappanavar R, Twardy BS, Krishna P, Suvas S. Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells. Mech Ageing Dev. 2009;130:709-12.
48. Lerner A, Yamada T, Miller RA. Pgp-1hi T lymphocytes accumulate with age in mice and respond poorly to concanavalin A. Eur J Immunol. 1989;19:977-82.
49. Li SP, Cai Z, Shi W, Brunmark A, Jackson M, Linton PJ. Early antigen-specific response by naive CD8 T cells is not altered with aging. J Immunol. 2002 15;168:6120-7.
50. Norian LA, Allen PM. No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with aging. J Immunol. 2004;173:835-44.
51. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol. 2006;126:25-31.
52. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995;375:155-8.
53. Zheng BJ, Chan KW, Im S, Chua D, Sham JS, Tin PC, He ZM, Ng MH. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int J Cancer. 2001;92:421-5.
54. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9 V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173:6767-76.
55. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-6.
56. Colonna-Romano G, Potestio M, Aquino A, Candore G, Lio D, Caruso C. Gamma/delta T lymphocytes are affected in the elderly. Exp Gerontol. 2002;37:205-11.
57. Argentati K, Re F, Donnini A, Tucci MG, Franceschi C, Bartozzi B, Bernardini G, Provinciali M. Numerical and functional alterations of circulating gammadelta T lymphocytes in aged people and centenarians. J Leukoc Biol. 2002;72:65-71.
58. Re F, Donnini A, Bartozzi B, Bernardini G, Provinciali M. Circulating gammadelta T cells in young/adult and old patients with cutaneous primary melanoma. Immun Ageing. 2005;2:2.
59. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol. 2011;23:146-52.
60. Sprecher E, Becker Y, Kraal G, Hall E, Harrison D, Shultz LD. Effect of aging on epidermal dendritic cell populations in C57BL/6J mice. J Invest Dermatol. 1990;94:247-53.
61. Belsito DV, Epstein SP, Schultz JM, Baer RL, Thorbecke GJ. Enhancement by various cytokines or 2-beta-mercaptoethanol of Ia antigen expression on Langerhans cells in skin from normal aged and young mice. Effect of cyclosporine A. J Immunol. 1989;143:1530-6.
62. Choi KL, Sauder DN. Epidermal Langerhans cell density and contact sensitivity in young and aged BALB/c mice. Mech Ageing Dev. 1987;39:69-79.
63. Hazlett LD, Moon MM, Dawisha S, Berk RS. Age alters ADPase positive dendritic (Langerhans) cell response to P. aeruginosa ocular challenge. Curr Eye Res. 1986;5:343-55.
64. Tourkova IL, Yamabe K, Foster B, Chatta G, Perez L, Shurin GV, Shurin MR. Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate. 2004;59:203-13.
65. Zavala WD, Cavicchia JC. Deterioration of the Langerhans cell network of the human gingival epithelium with aging. Arch Oral Biol. 2006;51:1150-5.
66. Wulf HC, Sandby-Møller J, Kobayasi T, Gniadecki R. Skin aging and natural photoprotection. Micron. 2004;35:185-91.
67. Teig N, Moses D, Gieseler S, Schauer U. Age-related changes in human blood dendritic cell subpopulations. Scand J Immunol. 2002;55:453-7.
68. Shodell M, Siegal FP. Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing. Scand J Immunol. 2002;56: 518-21.
69. Della Bella S, Bierti L, Presicce P, Arienti R, Valenti M, Saresella M, Vergani C, Villa ML. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol. 2007;122:220-8.
70. Steger MM, Maczek C, Grubeck-Loebenstein B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol. 1996;105:544-50.
71. Steger MM, Maczek C, Grubeck-Loebenstein B. Peripheral blood dendritic cells reinduce proliferation in in vitro aged T cell populations. Mech Ageing Dev. 1997;93:125-30.
72. Lung TL, Saurwein-Teissl M, Parson W, Schönitzer D, Grubeck-Loebenstein B. Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine. 2000;18:1606-12.
73. Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M. Surface markers and transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol. 2000;35:213-24.
74. Varas A, Sacedón R, Hernandez-López C, Jiménez E, García-Ceca J, Arias-Díaz J, Zapata AG, Vicente A. Age-dependent changes in thymic macrophages and dendritic cells. Microsc Res Tech. 2003;62:501-7.
75. Grolleau-Julius A, Garg MR, Mo R, Stoolman LL, Yung RL. Effect of aging on bone marrow-derived murine CD11c+CD4-CD8alpha-dendritic cell function. J Gerontol A Biol Sci Med Sci. 2006;61:1039-47.
76. Castle SC, Uyemura K, Crawford W, Wong W, Klaustermeyer WB, Makinodan T. Age-related impaired proliferation of peripheral blood mononuclear cells is associated with an increase in both IL-10 and IL-12. Exp Gerontol. 1999;34:243-52.
77. Uyemura K, Castle SC, Makinodan T. The frail elderly: role of dendritic cells in the susceptibility of infection. Mech Ageing Dev. 2002;123: 955-62.
78. Grolleau-Julius A, Harning EK, Abernathy LM, Yung RL. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res. 2008;68:6341-9.
79. Sharma S, Dominguez AL, Lustgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol. 2006;41:78-84.
80. Shi M, Bi X, Xu S, He Y, Guo X, Xiang J. Increased susceptibility of tumorigenicity and decreased anti-tumor effect of DC vaccination in aged mice are potentially associated with increased number of NK1.1+CD3+ NKT cells. Exp Oncol. 2005;27:125-9.
81. Linton PJ, Li SP, Zhang Y, Bautista B, Huynh Q, Trinh T. Intrinsic versus environmental influences on T cell responses in aging. Immunol Rev. 2005;205:207-19.
82. Li Y, McGowan P, Hellström I, Hellström KE, Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421-8.
83. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol. 2004;173:4510-5.
84. Sharma S, Dominguez AL, Lustgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-0X40 or anti-4-1BB. Exp Gerontol. 2006;41:78-84.
85. Ruby CE, Weinberg AD. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother. 2009;58:1941-7.
86. Ruby CE, Weinberg AD. 0X40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol. 2009;182:1481-9.
87. Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol. 2002;169:5005-9.
88. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hämmerling GJ. NK-and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001;167:5247-53.
89. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T cell responses and antitumor immunity. J Immunother. 2005;28:220-8.
90. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Tolllike receptor expression and function in aging. J Immunol. 2002;169:4697-701.
91. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.
92. Sharma S, Dominguez AL, Hoelzinger DB, Lustgarten J. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother. 2008;57:549-61.
93. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-405.
94. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
95. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618-31.
96. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
97. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, Nayak L, Moss PA. The number of human peripheral blood CD4+ CD25 high regulatory T cells increases with age. Clin Exp Immunol. 2005;140:540-6.
98. Sharma S, Dominguez AL, Lustgarten J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol. 2006;177:8348-55.
99. Pan XD, Mao YQ, Zhu LJ, Li J, Xie Y, Wang L, Zhang GB. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice. Chin Med J (Engl). 2012;125:2004-11.
100. Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, Wang J, Mountz JD, Zhang HG. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev. 2007;128: 672-80.
101. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013;93:633-7.
102. Fulop T, Larbi A, Douziech N, Levesque I, Varin A, Herbein G. Cytokine receptor signalling and aging. Mech Ageing Dev. 2006;127:526-37.
103. Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, Thibodeaux SR, Pandeswara S, Murthy K, Livi CB, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res. 2012;72:2089-99.